Patents by Inventor Jiuling Yang

Jiuling Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MDM2 PROTEIN DEGRADERS
    Publication number: 20220411432
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1??I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Application
    Filed: August 31, 2021
    Publication date: December 29, 2022
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • MDM2 protein degraders
    Patent number: 11192898
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: December 7, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • SMALL MOLECULE MDM2 PROTEIN DEGRADERS
    Publication number: 20210309666
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Application
    Filed: June 9, 2021
    Publication date: October 7, 2021
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • Small molecule MDM2 protein degraders
    Patent number: 11046703
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20210002289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: August 31, 2020
    Publication date: January 7, 2021
    Inventors: Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • Monofunctional intermediates for ligand-dependent target protein degradation
    Patent number: 10759808
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • SMALL MOLECULE MDM2 PROTEIN DEGRADERS
    Publication number: 20200109149
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 9, 2020
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • MDM2 PROTEIN DEGRADERS
    Publication number: 20190127387
    Abstract: The present disclosure provides compounds represented by Formula I-A: A1-L1-B1 I-A and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein A1, B1, and L1 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to degradation of MDM2 protein such as cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: May 2, 2019
    Inventors: Shaomeng Wang, Yangbing Li, Jiuling Yang, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Rohan Rej, Xin Han
  • MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION
    Publication number: 20190119289
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 25, 2019
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang